Online CME

Series Activities

Series Activities

Cleveland Clinic Tumor Boards

Optimal Management of Men with Locally-Advanced and Metastatic Hormone-Sensitive Prostate Cancer

Print this Content

Release Date:   March 9, 2018
Expiration Date:   March 9, 2019

Estimated Time of Completion:   45 minutes

Description

The Optimal Management of Men with Locally-Advanced and Metastatic Hormone-Sensitive Prostate Cancer (mCSPC) webcast reviews and discusses the evolving changes in the management of men with locally-advanced and metastatic prostate cancer. Using real-life clinical cases as a platform, the expert faculty roundtable will discuss existing and emerging data that all practitioners can use to maximize the outcome of men with mCSPC.

Learning Objectives

  1. Discuss current standards of care for patients with metastatic hormone (castration)-sensitive prostate cancer (mCSPC).
  2. Discuss key results of clinical trials evaluating docetaxel plus luteinizing-hormone releasing hormone (LHRH) agonists or abiraterone/prednisone plus LHRH for the treatment of mCSPC.
  3. Assess the rationale, efficacy, and safety of docetaxel and abiraterone/prednisone in recent clinical trials of mCSPC.
  4. Assess the prospective and retrospective evidence for local therapy in the management of mCSPC.
  5. Define oligometastases and explain the rationale for site-directed disease management.

Target Audience

This online series is designed for medical, radiation, and surgical oncologists, urologists, oncology practice managers, doctors of nursing practice, nurse practitioners, physician assistants, oncology clinical pharmacists, oncology advanced practice nurses, and other clinicians involved in oncology care delivery.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors and Faculty

Activity Directors

Jame Abraham, MD
Director, Breast Oncology Program
Co-Director, Comprehensive Breast Cancer Program
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Jorge A. Garcia, MD, FACP
The Kerscher Family Chair for Clinical Prostate Cancer Research
Department of Hematology/Oncology and Urology
Taussig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH

Faculty

Terence Friedlander, MD
Associate Professor of Medicine
Hematology/Oncology
University of California, San Francisco
San Francisco, CA

Elisabeth I. Heath, MD, FACP
Associate Center Director, Translational Sciences
Hartmann Endowed Chair for Prostate Cancer Research
Professor of Oncology
Karmanos Cancer Institute/Wayne State University School of Medicine
Detroit, MI

Andrew J. Stephenson, MD, MBA, FRCSC, FACS
Director, Urologic Oncology
Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH

Rahul Tendulkar, MD
Associate Professor of Medicine
Department of Radiation Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentations, could be perceived as a potential conflict of interest:


Jame Abraham, MD
  Genentech/Roche Teaching and Speaking
  Pfizer, Inc. Consulting; Teaching and Speaking
 
Terence Friedlander, MD
  Janssen Independent contractor (including contracted research)
  Astellas Pharma US, Inc. Teaching and Speaking
  Genenetch/Roche; Pfizer; Astra Zeneca Consulting
 
Jorge A. Garcia, MD, FACP
  Astellas Pharma US, Inc.; Bayer Healthcare; Sanofi Aventis Consulting; Teaching and Speaking
  Clovis Oncology; Exelixis; Genentech/Roche Consulting
 
Elisabeth I. Heath, MD, FACP
  Sanofi Aventis Membership on advisory committee or review panels; Teaching and Speaking

The following faculty have indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Andrew J. Stephenson, MD, MBA, FRCSC, FACS
Rahul Tendulkar, MD


All other planners, CME staff, and content reviewers, have no relevant financial relationships to disclose.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:

Astellas and Medivation, Inc., a Pfizer company

This CME activity was produced by
Cleveland Clinic Foundation Center for Continuing Education,
Taussig Cancer Institute and Harborside Press.